Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 7677 results

  1. Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancer

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  2. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]

    In development [GID-TA11495] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  5. Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]

    Awaiting development [GID-TA11346] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. myCOPD for managing chronic obstructive pulmonary disease (MTG68)

    Evidence-based recommendations on myCOPD for managing chronic obstructive pulmonary disease.

    Medical technologies guidance
    Published
    31 March 2022
    View recommendations

    Sections for MTG68

  7. MT547 QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

      Status ...

    Medical technologies guidance
    Topic selection

  8. Suspected cancer update

    In development [GID-QS10176] Expected publication date: TBC

    Quality standard
    In development

  9. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

    In development [GID-TA11513] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  10. CytoSorb for reducing risk of bleeding during cardiac surgery

      Status ...

    Medical technologies guidance
    Topic selection

  11. Moor LDLS-BI for assessing burn depth and healing potential in children and adults

      Status ...

    Medical technologies guidance
    Topic selection

  12. The Stak for knee stretching following knee replacement or injury or to treat osteoarthritis

      Status ...

    Medical technologies guidance
    Topic selection

  13. DOASENSE DOAC dipstick product for the detection of direct oral anti-coagulants

      Status ...

    Diagnostics guidance
    Topic selection

  14. URO17 for testing suspected bladder cancer

      Status ...

    Diagnostics guidance
    Topic selection

  15. RenalSense Clarity RMS for acute kidney injury MT601 (MIB256)

      Status ...

    Medical technologies guidance
    Topic selection